Management of hypertension in ethnic minorities

Heart

Volumn 91, Issue 8, 2005, Pages 1105-1109

  Khan, Jawad M ^a   Beevers, D Gareth ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ETHNIC GROUP; HEALTH SURVEY; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; LIFESTYLE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE DISTRIBUTION; AGED; ANTIHYPERTENSIVE AGENTS; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERTENSION; LIFE STYLE; MIDDLE AGED; MINORITY GROUPS;

EID: 23044445116     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.044560     Document Type: Review

References (32)

1. Mayet J, Brady A. Hypertension: special issues in different ethnic groups. New perspectives in hypertension. Brady, Petrie: Merit Publishing International, 2003:124-9.
2. Beevers DG, Lip GYH, O'Brien E. ABC of hypertension, 4th ed. London: BMJ Publishing Group, 2001:12.
3. Lane DA, Lip GYH, Ethnic differences in hypertension, blood pressure control in the UK. QJM 2001;94:391-6. An excellent review detailing the prevalence, treatment, and clinical implications of hypertension in ethnic minority groups in the UK. The review clarifies the conflicting epidemiological data on ethnic differences in blood pressure in the UK.
4. Cappuccio FP, Cook DG, Atkinson RW, et al. Prevalence, detection, and management of cardiovascular risk factors in different ethnic groups in South London. Heart 1997;78:555-63.
5. McKeigue PM, Shah B, Marmot MG. Relationship of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet 1991;344:450-2.
6. Agyemang C, Bhopal RS. Hypertension and coronary heart disease in South Asians. The epidemic of coronary heart disease in South Asian populations: causes and consequences. South Asian Heart Foundation, 2003:108. Data from an authoritative book on cardiovascular disease in the South Asian population in the UK. The book was published by the South Asian Heart Foundation and describes evidence based practice to reduce the high burden of cardiovascular disease in South Asians.
7. Cruickshank JK, Beevers DG, Osbourne VL, et al. Heart attack, stroke, diabetes, and hypertension in West Indians, Asians and whites in Birmingham, England. BMJ 1980;281:1108.
8. Balarajan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996;28:45-51.
9. Raleigh VS, Kiri V, Balarajan R. Variations in mortality from diabetes mellitus, hypertension and renal disease in England and Wales by country of birth. Health Trends 1997;28:122-7.
10. Chaturvedi N. Ethnic differences in cardiovascular disease. Heart 2003;89:681-6. A review article that comprehensively describes the striking ethnic differences in cardiovascular disease risk. It details the differences in modes of presentation of disease and therapeutics necessitating an increased awareness among healthcare professionals of cultural differences.
11. Hall WD. Cardiovascular therapy in black patients. In: Messerli FH, ed. Cardiovascular drug therapy. Philadelphia: Sounders, 1996:280-91.
12. Aloia JF, Vaswani A, Ma R, et al. Sodium distribution in black and white women. Miner Electrolyte Metab 1997;23:74-8.
13. Cho JH, Nash F, Fekete Z, et al. Increased calcium stores in platelets from African Americans. Hypertension 1995;25:377-83.
14. Freis ED, Materson BJ, Flamenbaum W. Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system. Am J Med 1983;74:1029-41. An interesting study looking at the relationship between renin activity and therapeutic response to hydrochlorothiazide and propranolol.
15. Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE) [erratum in JAMA 1998;279:1954]. JAMA 1998;279:839-46.
16. Matlou SM, Isles CG, Higgs A, et al. Potassium supplementation in blacks with mild to moderate essential hypertension. J Hypertens 1986;4:61-4.
17. Williams B, Poulter NR, Morris JB, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). BMJ 2004;328:634-40. Latest update of the BHS incorporating new epidemiological data on cardiovascular disease risk and the importance of systolic hypertension as a determinant of risk. The guidelines hope to address the suboptimal management of hypertensive patients in the UK.
18. He FJ, Markandu ND, Sagnella GA, et al. Salt restriction in Europeans and Afro-Caribbeans. Hypertension 1998;32:820-4.
19. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension: I. Results of short-term titration with emphasis on racial differences in response. JAMA 1982;248:1996-2003. An early study showing evidence of the increased efficacy and sensitivity of black patients to thiazide diuretics compared to whites. The study showed that race was an important determinant in deciding first line drug treatment.
20. Laragh JH, Cannon PJ, Stason WB, et al. Physiologic and clinical observations on furosemide and ethacrynic acid. Ann N Y Acad Sci 1966;139:453-65.
21. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-21. An excellent study with direct comparison of six antihypertensive drugs with placebo in mild to moderately severe hypertension. Efficacy according to age and race was also determined, showing that antihypertensive treatment should be tailored to individual patients.
22. Ventura HO, Frohlich ED, Messerli FH, et al. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. Am J Cardiol 1985;55:1023-6.
23. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
24. Hall WD, Israili ZI. The use of ACE inhibitors in blacks and whites. In: Schachter M, ed. ACE inhibitors: current use and future prospects. London: Dunitz, 1995:123-43.
25. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blacker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990;150:1707-13. A direct comparison of the efficacy and safety of atenolol, captopril, and sustained release verapamil in black patients. This study showed that side effects of all three were minimal and comparable and that verapamil was the most effective agent.
26. Weir MR, Chrysant SG, McCarron DA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998;31:1088-96.
27. Moser M, Prisant LM. Low-dose combination therapy in hypertension [editorial]. Am Fam Physician 1997;56:1275-6, 1279, 1282.
28. Materson BJ. Lessons on the interaction of race and antihypertensive drugs from the VA cooperative study group on antihypertensive agents. Am J Hypertens 1995;8(12 pt 2):91S-3S.
29. Bakris GL, Copley JB, Vicknair N, et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50.
30. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797-810.
31. Sehgal AR. Meta analysis of monotherapy in black and white hypertensives. Hypertension 2004;43:566-72. A comprehensive meta-analysis on more than 12 000 patients quantitating how often black and white patients have similar responses to specific antihypertensive drugs.
32. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288:2981-97. With over 42 000 patients ALLHAT was the largest randomised control trial of antihypertensive treatment to date and included 15 094 black patients. It snowed that thiazide type diuretics provided effective treatment at low cost.